Aurora Cannabis Inc (NYSE:ACB) has been given an average rating of “Buy” by the eleven research firms that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.04.
ACB has been the topic of several recent research reports. Desjardins reiterated a “buy” rating on shares of Horizons Enhcd Inc Eqy Cl E Unt Etf in a research note on Thursday, April 25th. TheStreet upgraded shares of TELUS from a “c+” rating to a “b-” rating in a research note on Thursday, April 4th. Stifel Nicolaus lowered their price objective on shares of MacroGenics from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, June 5th. Bank of America reiterated a “buy” rating and issued a C$10.00 price objective on shares of Hexo in a research note on Wednesday, April 17th. Finally, Zacks Investment Research cut shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a research note on Monday, May 20th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACB. LPL Financial LLC bought a new position in Aurora Cannabis during the fourth quarter worth about $870,000. Private Advisor Group LLC bought a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $551,000. Stephens Inc. AR bought a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $124,000. Bank of New York Mellon Corp bought a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $6,517,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $1,631,000. Institutional investors own 9.00% of the company’s stock.
Aurora Cannabis (NYSE:ACB) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.05). Aurora Cannabis had a positive return on equity of 1.24% and a negative net margin of 122.65%. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $50.92 million. On average, equities research analysts forecast that Aurora Cannabis will post -0.22 EPS for the current year.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Further Reading: Discount Rate
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.